Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crown

Showing results (161-170 of 188) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast CancerParvin F Peddi, Peter A Fasching, Duan Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsMichael F Press, Guido Sauter, Marc Buyse, et al.
The Oncologist|July 2, 2013
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 StudyHeather-Jane Au, Wolfgang Eiermann, Nicholas J Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press, Guido Sauter, Marc Buyse, et al.
Breast Cancer Research : BCR|January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerPeter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
Molecular Cancer Therapeutics|October 16, 2004
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelVirginie Durbecq, Marianne Paesmans, Fatima Cardoso, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
The New England Journal of Medicine|October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancerDennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.
NPJ Breast Cancer|September 27, 2023
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancerNicola Cosgrove, Alex J Eustace, Peter O'Donovan, et al.
JAMA Oncology|September 25, 2025
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical TrialPeter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, et al.
Pageof 19

Showing results (161-170 of 188) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast CancerParvin F Peddi, Peter A Fasching, Duan Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsMichael F Press, Guido Sauter, Marc Buyse, et al.
The Oncologist|July 2, 2013
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 StudyHeather-Jane Au, Wolfgang Eiermann, Nicholas J Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press, Guido Sauter, Marc Buyse, et al.
Breast Cancer Research : BCR|January 16, 2021
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerPeter Schmid, Marie-Paule Sablin, Jonas Bergh, et al.
Molecular Cancer Therapeutics|October 16, 2004
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelVirginie Durbecq, Marianne Paesmans, Fatima Cardoso, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
The New England Journal of Medicine|October 14, 2011
Adjuvant trastuzumab in HER2-positive breast cancerDennis Slamon, Wolfgang Eiermann, Nicholas Robert, et al.
NPJ Breast Cancer|September 27, 2023
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancerNicola Cosgrove, Alex J Eustace, Peter O'Donovan, et al.
JAMA Oncology|September 25, 2025
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical TrialPeter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, et al.
Pageof 19